Discover how NEO-201, an investigational monoclonal antibody, targets tumor-associated neoepitopes and abnormal O-glycans to enhance antibody-dependent cellular cytotoxicity (ADCC), reshape the tumor microenvironment, and potentially synergize with checkpoint inhibitors in solid tumor treatment.
Learn how erenumab (Aimovig), a CGRP receptor‑blocking monoclonal antibody, differs from traditional migraine drugs like beta‑blockers and antidepressants. Explore its targeted mechanism, once‑monthly dosing, and clinical trial results for episodic and chronic migraine prevention.
Learn how erenumab, a CGRP receptor–blocking monoclonal antibody, is transforming migraine prevention. Discover its mechanism, benefits for episodic and chronic migraine, and why it outperforms many traditional oral preventives.